In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $9.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cory Jubinville, PhD has given his Buy rating due to a combination of factors including Rocket Pharmaceuticals’ regained momentum and strategic progress in their pipeline. The company has achieved significant milestones such as aligning with the FDA to resume the pivotal Phase 2 trial for RP-A501 in Danon disease, and the FDA’s acceptance of the BLA resubmission for KRESLADI for LAD-I, which is a positive indicator for future approvals.
Additionally, Rocket Pharmaceuticals has shown disciplined execution and strategic focus across its cardiovascular portfolio, with continued FDA engagement on RP-A601 and the initiation of a Phase 1 study for RP-A701. The company’s financial position is also strong, with cash and investments providing an operational runway into Q2 2027, which supports its ongoing and future projects. These factors collectively contribute to the positive outlook and the Buy rating for Rocket Pharmaceuticals’ stock.